Nordic collaboration cancer care pathways Agenda 11.00 Welcome - - PowerPoint PPT Presentation

nordic collaboration cancer care pathways
SMART_READER_LITE
LIVE PREVIEW

Nordic collaboration cancer care pathways Agenda 11.00 Welcome - - PowerPoint PPT Presentation

Nordic collaboration cancer care pathways Agenda 11.00 Welcome 11.10 Aim of the network 11.30 Selection of board for the network 11.45 Status for cancer care pathways in Sweden 12.00 Lunch 13.00 Status for cancer care pathways in Denmark and


slide-1
SLIDE 1

Nordic collaboration cancer care pathways

Agenda 11.00 Welcome 11.10 Aim of the network 11.30 Selection of board for the network 11.45 Status for cancer care pathways in Sweden 12.00 Lunch 13.00 Status for cancer care pathways in Denmark and Norway 13.30 Cancer care pathways in Finland 14.15 Coffee 14.45 Ongoing research 16.45 Closing Remarks

slide-2
SLIDE 2

Ongoing research

  • A comparative Study of introducing standardized patient pathway as

health care reform in the three Scandinavian countries. (Per Magnus

Maehle, Senada Hajdarevic, Rikke Aarhus, Erna Håland)

  • Identification and early detection of cancer patients in primary care.

(Marcela Ewing)

  • Elderly Cancer Patients in Denmark - Routes to diagnosis, treatment and
  • prognosis. (Bolette Danckert)
  • Exploring the implementation of the standardized cancer patient pathways

(CPPs) in Sweden- a qualitative study. (Sara Ronja-Li Delilovic)

  • Crowding out effects, what is the consequences in introducing

standardized patient pathway. (Sara Ronja-Li Delilovic)

  • Bacteriuria and other risk modulating factors for urothelial cancer in

patients with macroscopic hematuria-A study made possible by the SVF investigation protocols. (Oskar Kulander)

slide-3
SLIDE 3

Nordic collaboration cancer care pathways- Background

  • Meeting in Stockholm, Oslo and København
  • Areas for collaboration:

– Diagnostic centres – Equal care – Patient experience – National cohorts – Coordinator – Individualized vs standardized care – Crowding out/side effects

  • Funding:
  • Swedish government- one meeting/year
  • Nordic Cancer Union- meeting, webbsite, common workspace (projectplace)
  • Application to Nordic council of ministers (Nordiska ministerrådet) TBD 15-16 nov
slide-4
SLIDE 4

Webbsite

  • Contact information
  • Description of ongoing projects
  • Reporting on publications
slide-5
SLIDE 5

Projectplace

  • Common workplace where we can share documents, communicate within

the goups and with subgroups

  • Check out Webinars and videos on how to work in projectplace
slide-6
SLIDE 6

Forming of Steering Committe

  • Two representatives from each country

– Denmark: Linda Aagaard Thomsen, Henry Jensen – Finland:? – Iceland:? – Norway: Line Melby, Sissi Espetvedt – Sweden: Helena Brändström, Marcela Ewing

  • Responsibilites:

– Arrange meeting(s) and workshop(s) – Decide on project support – Other functions?

slide-7
SLIDE 7

Discussion in groups

  • Responsibilites for steering Committe?
  • Do we need common workspace and webbsite?
  • New areas of collaboration
  • Which groups are viable:

– Diagnostic centres – Equal care – Patient experience – National cohorts – Coordinator – Individualized vs standardized care – Crowding out/side effects

  • Contact person in each group?
slide-8
SLIDE 8

500 million Swedish kronor 2015 – 2018 to

  • Reduce waiting times
  • Reduce regional differences
  • More equal care with increased quality

and improve patient experience

  • More predictive care for the patients
slide-9
SLIDE 9

Status Cancer patient pathways (pakkeforlob) in Sweden

  • Last year of initial governmental focus on CPP

(2015-2018)

  • All political parties (except Sverigedemokraterna)

have annonuced a continuation with at least 500 000 000 SEK/ year for at least 4 more years

  • 31 CPP implemented, only adults
  • On national level: follow-up on waiting times and

patient experience measurements (PREM)

  • County councils responsible for implementation

and report every half year to the governement on status of the work.

slide-10
SLIDE 10

Where are we going?

Goal for 2020

  • 70 % of patients should be included in CPP
  • 80 % of patients sholud be diagnosed and start treatment within the maximum

lead time

slide-11
SLIDE 11

Where are we now?

slide-12
SLIDE 12

Patients included in SVF (goal 70%)

slide-13
SLIDE 13

Patient reported experience measurements (PREM)

No of patients starting treatment

slide-14
SLIDE 14

Waiting times a big problem in Sweden

170328 SKL | Varje erfarenhet räknas

Trend curve showing amount of patients where the watinig time is shorter than ”vårdgarantin 90 days” Treatement of malignanices are not included (Källa: www.vantetider.se)

slide-15
SLIDE 15

Also in cancer care

slide-16
SLIDE 16

Waiting times cancer patient pathways?

slide-17
SLIDE 17

Waitning times breast cancer

170328 SKL | Varje erfarenhet räknas

slide-18
SLIDE 18

Obstacles!

  • Increasing/not decreasing waiting time due to shortages of

personell for example nurses

  • IT-systems!! Problems to get accurate reproting on waiting times

for CPP

  • Reporting of CPPs over county council boundaries
  • Crowding-out effects are under discussion.

2018-02-02 Helena Brändström | SVF-dag RCC Väst

slide-19
SLIDE 19

Better results in many places

170328 SKL | Varje erfarenhet räknas

slide-20
SLIDE 20

TACK!

Helena.brandstrom@skl.se

slide-21
SLIDE 21

Ongoing research

  • A comparative Study of introducing standardized patient pathway as

health care reform in the three Scandinavian countries. (Per Magnus

Maehle, Senada Hajdarevic, Rikke Aarhus, Erna Håland)

  • Identification and early detection of cancer patients in primary care.

(Marcela Ewing)

  • Elderly Cancer Patients in Denmark - Routes to diagnosis, treatment and
  • prognosis. (Bolette Danckert)
  • Exploring the implementation of the standardized cancer patient pathways

(CPPs) in Sweden- a qualitative study. (Sara Ronja-Li Delilovic)

  • Crowding out effects, what is the consequences in introducing

standardized patient pathway. (Sara Ronja-Li Delilovic)

  • Bacteriuria and other risk modulating factors for urothelial cancer in

patients with macroscopic hematuria-A study made possible by the SVF investigation protocols. (Oskar Kulander)

slide-22
SLIDE 22

170328 SKL | Varje erfarenhet räknas

Closing remarks

  • Next meeting- Norway!
  • Theme: Alarm symptoms, comparisons of Nordic

cohorts other?

  • Criteria for application to support projects?
  • Ongoing projects that need support?
slide-23
SLIDE 23

170328 SKL | Varje erfarenhet räknas